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To investigate whether the immunosuppressive neuropeptide 
calcitonin gene related peptide (CGRP) was a potential candidate for 
tissue-specific gene therapy, we engineered Non-Obese Diabetic 
(NOD) mice to produce CGRP in beta cells by placing the modified 
calcitonin gene under the control of the rat insulin promoter. CGRP 
inhibits the production of cytokines by Thl cells which have been 
implicated in the pathogenesis of type I diabetes. Three transgene 
positive mouse lines were obtained, two of which express 
immunoreactive CGRP in beta cells (NOD-CGRP mice). Isolated islets 
from one of these two transgene positive founders produced active 
CGRP while islets from transgene negative mice did not. The 
production of CGRP by beta cells prevents IDDM in male, and 
reduces its incidence by 63 % in female NOD mice. This 
immunosuppressive effect of CGRP is due to a local effect and not a 
systemic effect of CGRP on peripheral lymphoid organs as no 
difference was detected between NOD-CGRP and NOD mice lymph 
node, spleen and thymus cells by either fluorescence-activated cell 
sorter analysis or proliferative response to stimulation by antigen, 
alloantigen or anti-CD3. CGRP partially prevented peri-insulitis in 
NOD-CGRP mice whose lymphoid cell composition was similar to that 
of NOD mice, further suggesting the local immunoregulatory effect of 

CGRP. These data suggest that CGRP is a potential therapeutic 
molecule to prevent or treat diabetes and possibly other diseases and 
conditions in which immune cells are involved. These data also 
suggest that endogenous CGRP concentrated in sensory nerve 
endings may regulate locally in tissues the immune response, further 




2.1 Establishment of Reference Point 
BALANCE + SIMPLICITY = EXISTENCE 
At a very basic level to defend a thesis, a reference point is 
required. As odd as it may seem. I have chosen the above equation as 
that reference point. .Arguably the goal of life at a rudimentary level 
is existence. If this is the case, then I believe that the requirements 
of existence from an evolutionary point of view are balance and 
simplicity. During existence an organism is subjected primarily to 
two main forces: environmental and evolutionary, which are one and 
the same but on a different time scale. Environment mandates 
balance and evolution mandates simplicity. 
Balance implies some arbitrary midpoint in between two 
extremes, between high or low, between much or little. Further 
implication is that an organism that is in balance can exist within the 
range of the two extremes and, if subjected to environmental forces, 
can shift its balance in one direction or the other to adapt 
accordingly. The time scale between the stimulus (an environmental 
force) and the response (shift in balance) is small. 
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Evolution, on the other hand, exerts its influence on a much 
larger time scale. Evolutionary change is determined by the 
functional efficiency (adaptedness) of the organism in its 
environment1. Webster's dictionary defines efficiency as an “ability to 
produce a desired effect . . . with a minimum of effort, expense, or 
waste.” Any given organism must perform numerous biological 
functions in order to survive. Each and every one of these functions 
must be performed with the least amount of effort, expense and 
waste. If ten competitors involved in a contest were asked to design 
a system to perform a certain function, surely the simplest design 
with the least number of steps would win. unless a different design, 
even if it involved a few more steps, could be shown to perform that 
function much better. Over billions of years every step of the 
evolution has been put to the same test by nature. A human being, 
which some may egocentricallv believe to be the epitome of the 
evolutionary design, may seem quite complex at first glance. 
However, it is a large system comprised of indefinite number of 
simpler subsystems each performing its assigned function in the 
most efficient manner. It is of vital importance to realize that this is 
not a system whose mechanism can be explained by linear dynamics, 
rather it is a system comprised of extensive nonlinear networks 
which at every step simply self-regulate through a multitude of 
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feedback mechanisms. Finally, to paraphrase a well known saying, 
evolution is the survival of the fittest and the simplest. 
Most if not all of science is the study of nature and of existence 
in particular. Through the ages nature has selected to travel down 
the path of simplicity and balance. Consequently, if we are to unravel 
and explain the “way of nature," then we must abide by its rules and 
follow the same path it has taken. Following the gathering of data, 
teleologically we must strive to formulate the simplest possible 
theory consistent with all that is known and with balance as its 
fundamental tenet. 
2.2 Autoimmune Disease 
Understanding complex biological systems is a great challenge. 
Every discovery represents an individual piece of information that 
needs to be arranged in its respective place without knowing with 
certainty how the pieces interrelate. With this in mind theories are 
introduced as to what the overall picture may look like and how the 
individual pieces fit together. This is an essential step because just 
like in a jigsaw puzzle, even if all the pieces are present, if an 
incorrect picture is used as a guide, the puzzle cannot be solved. 
Various theories of how the immune system functions in a 
physiological setting have evolved within the past century. 
■ 
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We are taught that immunology is the science of self-nonself 
discrimination2. Yet the understanding of how the boundary between 
self and nonself is established is far from complete. What is certain is 
that under “normal” conditions self is tolerated while in an 
autoimmune disease, a breach in the self-nonself boundary takes 
place and self is no longer tolerated. To a great extent as a 
consequence of our incomplete understanding of immunophysiology, 
the definitive mechanism of autoimmue disease remains a mystery. 
However, enormous amount of work has been done in this field in the 
past half century. 
Burnet, in 1959, proposed the “clonal selection theory” and 
according to this theory the immune system during its development 
consists of ceils that possess within their repertoire receptors that 
are potentially self reactive. Self tolerance is established by a 
process of thymic deletion of self reactive T-cells, while cells that are 
reactive to foreign antigens are spared3. This process of self-reactive 
T-cell deletion has been confirmed as recently as 19874. During 
healthy states only immune cells that are capable of potentially 
binding foreign antigens exist and recognition of self is nonexistent. 
Autoimmune disease is bom when, for various reasons or purely by 
accident, elements of the immune system appear that recognize self 
and embark on a journey of self destruction". In other words 
autoimmune disease must result whenever a cell clone that was 
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eliminated during thymic education enjoys a reincarnation of sorts. 
In contradiction to this theory, various authors have reported that 
both T and B cells capable of autoimmune disease induction have 
been detected in the peripheral lymphoid tissues of healthy 
individuals67. Recently, Katz and his colleagues looked at the 
tolerance status of T cells bearing the transgenic, pathogenic T cell 
receptor (TCR) for self antigen responsible for insulin-dependent 
diabetis mellitus (IDDM) of the Non-Obese Diabetic(NOD) mouse 
model8. T cells with the transgenic TCR were not deleted as would 
have been predicted by the clonal selection theory. In fact, they 
interacted with self-antigens both in vitro and in vivo, and induced 
IDDM in these mice. 
Other observations, which also contradicted clonal selection 
theory, have led to the formation of alternative theories including the 
“idiotypic network theory.” This theory is based on the hypothesis 
that the immune system consists of both idiotypic and anti-idiotypic 
entities which through their interactions establish immunologic 
homeostasis. Autoimmune disease results as a consequence of 
aberrant and disproportionate proliferation of certain clones. The 
roots of this theory can be traced back to Jerne who in 1974 
proposed that self-reactivity is a normal component of the immune 
system whose major function is to maintain internal macromolecular 
homeostasis rather than protect the host from external invasion4. 

Barnett in early 1980's proposed the "primary lesion theory" 
which suggests that autoimmunity is not itself a distinct entity, but a 
physiological response to sustained antigen overproduction in 
diseased tissue, and fundamentally no different from the response to 
foreign antigen10. The phenomenon referred to as the “precipitating 
event in autoimmunity” is viewed as a primary lesion, whose 
continued presence is necessary to drive and sustain the response 
conventionally referred to as autoimmunity. Those who develop 
clinical disease are regarded as high responders to critical antigens 
generated in excess by the primary lesion. High responder status is 
determined by immune response, HLA-linked, genotype. The HLA 
class II (D region genes) are closely linked to immune reponse genes 
which control the response of specific clones". Thus, one strain of 
animal may fail to respond to an antigenic shape to which another 
strain of the same species reacts strongly. HLA phenotype is a good 
marker for such differences, and what applies to exogenous antigens 
also applies to autoantigens, but over a range of reactivity normally 
consistent with health. Barnett suggests that in type 1 diabetes, a 
primary rise in j3-cell antigen load is met with an expansion of 
specific and appropriate clones. The extent of clonal expansion 
relative to the antigen overload is HLA determined. Effector immune 
cells cannot distinguish diseased from healthy j^-ceils, and in the 
minority of those with the primary lesion who are high responders, 
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their greater number leads to inexorable destruction of all j3-cell 
tissue. 
Since cell products in excess are toxic and biologically active 
substances can cause various clinical syndromes, Barnett 
hypothesizes that “physiologic” autoimmunity may act as a defence 
mechanism in the face of antigen excess not only by neutralizing 
their biological or toxic effect on contact but by providing an 
alternative pathway for their clearance. Thus, although autoimmune 
disease may sometimes lead to organ destruction and death of the 
individual, it may have an advantageous defensive function for the 
species. 
All three of the theories discussed above attempt to explain the 
process of tolerance. A large body of evidence exists that both 
supports and contradicts these theories. Though the simplest, the 
clonal selection theory, because of its suggestion that autoreactive 
cells are categorically deleted during thymic education, is certainly 
lacking in balance. The idiotypic network theory, though more 
complex, incorporates balance as its fundamental building block. In 
fact, it goes hand in hand with the primary lesion theory. As 
idiotypic network theory suggests the immune system is utilized by 
the organism not only to ward off foreign invasion, but also to 
maintain internal homeostasis. When certain clones within the 
network disproportionately proliferate, they do so as a result of a 
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certain precipitating event. This precipitating event is viewed as the 
cornerstone of the primary lesion theory. Taken together, the 
idiotypic network theory and the primary lesion theory suggest a 
mechanism of tolerance and breakdown thereof, that lies within the 
realm of both simplicity and balance. 
2.3 Diabetes Mellitus 
2.3.1 Overview of Diabetes 
Diabetes is the name given to a constellation of symptoms 
arising from hyperglycemia. The disease can occur as a result of 
specific secondary causes ranging from iron overload of beta cells 
seen in hemochromatosis to insulin receptor defects. However, vast 
majority of patients with diabetes do not have a specific identifiable 
defect and are said to have idiopathic diabetes. 
It was little more than 20 years ago that diabetes was thought 
of as a single disease with more or less severe manifestations. The 
clinical distinction of more severe, ketosis-prone, insulin-dependent 
type (IDDM) and the more common, non-insulin-dependent type 
(NIDDM) had been recognized by clinicians for many years. In 1951, 
Lawrence and his colleagues proposed that diabetes could be divided 
into two main types: “[1] Those who are probably not insulin-deficient 
and [2] those who certainly are.” This observation was based on the 
studies that they performed on 10 diabetics: five young ketotic 
patients who they believed had insulin deficiency and five obese non- 

ketotic patients in whom diabetes was attributed to factors other 
than insulin deficiency12. Insulin level in these patients was 
estimated by injecting the patient’s plasma into alloxan-diabetic 
hypophysectomized and adrenalectomized rats. The fall in the blood 
glucose of the rats after 1 hour correlated with the amount of insulin. 
The five patients with ketosis had no insulin unlike the five non¬ 
ketotic patients who did. 
The first suggestion of significant difference between the two 
types diabetes came from identical twin studies. It w'as found that 
concordance was nearly one hundred percent in non-insulin 
dependent diabetics, but less than fifty percent in insulin dependent 
diabetics13. The proof of fundamental difference between the two 
types of diabetes came from a study published in 1974 that showed a 
strong association between certain HLA types and IDDM, but no such 
association was observed in NIDDM14. The authors believed that 
IDDM had an autoimmune basis and that viruses were also involved 
in the disease pathogenesis as was suggested by Gamble and his 
colleagues in earlier studies15. In that same year Bottazzo reported 
antibodies toward normal pancreatic islets cells in 13 patients with 
multiendocrine deficiencies16. All these observations were in 
concordance with reports made in 1950’s and 60’s regarding the 
presence of the inflammatory infiltrates in the pancreas of insulin- 
dependent diabetics17,18. In short, all these studies and many more 
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that have followed in the recent past have played a key role in the 
establishment of the current thinking that IDDM is caused by 
complete, autoimmune destruction of the beta cells of the pancreas. 
A summary of the main clinical characteristics of the two types 
of diabetes is presented in Table 1. In IDDM, hyperglycemia and 
ketosis appear suddenly in non-obese children or young adults and 
require chronic therapeutic intervention with small doses of insulin. 
The typical pathologic findings include insulitis followed by islet cell 
destruction. A strong association exists between IDDM and HLA DR3 
and DR4. On the other hand, NIDDM patients tend to present at an 
older age with symptoms of more chronic nature, are often obese and 
can be treated with dietary restrictions. In certain fraction of non- 
insulin-dependent diabetics amyloid deposits are found. Genetic 
predisposition is believed to be strong, however, no association with 
HLA types has been observed. In all populations NIDDM is much 
more common than IDDM, with the risk of developing NIDDM being 
more than 30 times greater19. 
2.3.2 Type 1 or Insulin-Dependent Diabetes Mellitus 
Following the establishment of IDDM as a fundamentally 
different disease from NIDDM, substantial body of research has been 
published on its etiology and pathogenesis. What is certain about the 
etiology of IDDM is that it involves a complex interplay between a 
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number of genetic and environmental factors. Genetic factors play 
an essential role as evidenced by the involvement of both MHC and 
non-MHC predisposition factors. In Caucasians increased prevalence 
of IDDM is seen in individuals with HLA DR3 and DR4 haplotypes. 
Furthermore, individuals who are DR3/DR4 heterozygotes have a 
twenty to forty fold higher risk than the general population20. In 
contrast, reduced prevalence is found in individuals with HLA DR2 
haplotype21. Other MHC associated genes associated with IDDM 
protection include Tap-1 and Tap-2 genes which code for 
transporters of antigenic peptides to MHC class I molecules22. 
Table 1: Main clinical characterics of the two types of diabetes (from “Insulin ” Aschroft 
and Aschroft. (1992) IRL Press.) 




Age of Onset Juvenile Onsetage 






usually 35 years or more 
usually obese 
often symptoms for years 
moderate hyperglycemia 




requires insulin therapy 
insulin sensitive (small doses of 
insulin needed) 
can be treated with diet or 
tablets 
insulin resistant (large doses 
of insulin needed) 
Pathology Type 1 diabetes 
islet cell antibodies present 
beta cells destroyed by immune 
inflammatory cells 
Type II diabetes 
islet cell antibodies absent 
often amyloid in islets 
Genetic Predisposition low concordance among 
identical twins 
associated with HLA DR3 and 
DR4 




Apart from the insulin gene, the search for the candidate non- 
MHC predisposing genes has been rather unfruitful in human IDDM. 
The 5’ region of the insulin gene has been shown to be associated 
with IDDM, independent of parental transmission and HLA type23. 
Heterozygosity of the beta chain of the T cell receptor (TCR) was 
reported in 1987 to have an association with IDDM24, however since 
then there has been no convincing evidence that TCR genes influence 
susceptibility to disease. Studies of the NOD mouse have led to the 
description of 10 non-MHC predisposition loci, in addition to the 
major association with MHC loci. These are discussed in more detail 
elsewhere in this paper under the subheading of NOD mice. 
Many of the studies described above establish genetic 
susceptibility as a required but not sufficient component of the 
disease process. As monozygotic twin studies have shown only 30- 
50% concordance of IDDM, it is environmental influences that 
provide the link between the diathesis and the disease. The 
importance of environmental factors are well established in animal 
models of spontaneous diabetes. In NOD mice variation of the diet2"1 
or several viral infections26,27 reduce disease susceptibility. 
In human populations it is much more difficult to establish 
specific direct links between environmental influences and and the 
development of IDDM. However, ample evidence exists that supports 
this hypothesis. Disease frequency varies greatly from country to 
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country with the greatest incidence found in Scandinavian 
countries2". It seems that in certain colder climates IDDM is found at 
a greater frequency. This is quite interesting, since it has been 
shown that by raising the ambient temperature the incidence of 
diabetes can be reduced in the NOD mice24. Studies of migrants from 
countries with low IDDM frequency to countries with high frequency 
have shown that they become more susceptible to disease in their 
new environment0,31. Other data from stable populations in Europe 
has shown a sudden surge in incidence of IDDM 2. This change in 
Europe represents a two to three-fold increase over a period of 30 
years and is clearly evidence that cannot be explained on genetic 
basis alone. Some of the environmental factors implicated as 
possible triggers of IDDM include viruses, most notably Coxsackie B 
virus33 and cytomegalovirus’4, bovine albumin found in cow’s milk'3, 
and even stress'6. The suggested hypothesis is that both Coxsackie B 
viral protein and bovine albumin share a sequence with the beta cell 
autoantigens, glutamic acid decarboxylase (GAD) and p69, 
respectively, and by virtue of molecular mimicry, immune reactions 
directed against the xenoantigens cross react with the beta cell 
autoantigens. 
The etiologic role of the environmental and genetic influences 
seem certain, but the nature and the extent of the contributions that 
each makes to the development of disease still requires much work. 
. 
Once the events that lead up to the break down of self tolerance have 
taken place, the details of the effector autoimmune cascade that 
follow seem clearer. Even though anti-islet cell antibodies have been 
demonstrated both in rodent and human IDDM, there is no evidence 
that these autoantibodies are pathogenic since the disease cannnot 
be transferred by the serum of the affected mice37. Without a doubt 
IDDM is a T-cell dependent autoimmune disease characterized by 
infiltration and destruction of the pancreatic islets by the cells of the 
immune system'8. Diabetes can be transferred to normal syngeneic 
animals by purified T cells from diabetic NOD mice'9. On the other 
hand diabetes can be prevented in NOD mice by anti-TCR 
monoclonal antibodies which selectively eliminate T cells40. The two 
subsets of T cells, CD4+ and CD8+, play different roles in this process 
(Figure 3). CD4+ T cells play an important role in both the 
recruitment and the activation of the immune effector cells. 
Lymphokines produced by CD4+ T cells include Interleukin-2 (IL-2), 
Interleukin-3 (IL-3), Interferon-y (IFN-y), Tumor Necrosis Factor-a 
(TNF-a), Tumor Necrosis Factor-j3 (TNF-J3) and Granulocyte- 
Macrophage Colony Stimulating Factor (GM-CSF). IFN-y, TNF-a and 
TNF-J3 have been shown to act as mediators of adhesion and 
extravasation for various inflammatory cells41. IL-2 induced 
proliferation of CD8+ T cells42 is one of the most crucial events in the 
pathogenesis of IDDM, for it is the army of CD8+ T cells that delivers 
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the major "cytotoxic” blow to the JTcell of the pancreas43. In addition 
to T cells, macrophages as well have been implicated in the 
destruction of the beta cells via local cytokine or free radical release. 
IL-1, which is released by activated macrophages, has been shown to 
have a cytotoxic effect on the pancreatic islets44. 
IDDM is clearly an autoimmune disease as reflected by the 
evidence given above, which represents a minute fraction of the 
existing body of scientific knowledge. Clear understanding of the 
etiology and the pathogenesis of IDDM still eludes us. However, given 
the astounding pace of modern science, the proximity of this 
presently elusive goal seems certain. 
2.4 Calcitonin Gene Related Peptide (CGRP) 
CGRP was first described by Rosenfeld and his colleagues in 198345. 
The story behind the discovery of this novel neuropeptide is quite 
interesting. Most peptides come to our attention as a result of 
certain biological function that they perform. The usual sequence of 
events include the purification of the peptide, followed by amino acid 
sequencing and lastly the identification of the gene that codes for the 
peptide. In the case of CGRP, everything was reversed as a 
consequence of recombinant DNA technology (Figure 4). 

Figure 4: 
The Usual Road Travelled 
|Biological|_^ 
| Function | 
Identification Ammo Acid Genomic DNA 
of the Peptide Sequence Analysis Sequence 
The Road Less Travelled 




Amino Acid Sequence 
Inferred From mRNASequence 
Peptide Isolated 
and Purified 
Numerous Functions Already Shown 
New Functions Still Being Discovered 
While Rosenfeld and his colleagues were studying the calcitonin gene 
transcription, they unexpectedly found a second, structurally distinct 
transcript, which they referred to as calcitonin gene related peptide 
mRNA. Through isolation and sequence analysis of the calcitonin 
genomic DNA, and calcitonin and CGRP cDNAs, they discovered that 
both CGRP and calcitonin mRNAs were generated by differential RNA 
processing from a single genetic locus46 (Figure 5). In the thyroid C 
cells the primary RNA transcripts are processed to mRNA for 
calcitonin, while mRNA for CGRP is formed predominantly in neural 
tissue47. Since its discovery, CGRP has become a subject of extensive 
research which has revealed the peptide’s important implications as 
a chemical messenger of the nervous system. 
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CGRP is co-localized and co-released with substance P in 
sensory nerves48 and with acetylcholine in motorneurons49. In the 
brain, CGRP is broadly distributed and especially concentrated in 
hypothalamic areas and some brainstem nuclei50. CGRP is ubiquitous 
in the peripheral tissues, including the digestive system"1. It has 
been detected in the blood stream52’53 54 and in the heart, 
predominantly in the atria, around coronary vessels and in the 
myocardium"8. 
A variety of biological effects have been attributed to CGRP, 
including the modulation of nicotinic receptor activities at the 
neuromuscular junction"6 and of substance P in inflammation"7, a 
reduction of gastric acid secretion58, potent peripheral blood vessel 
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dilation59'60'61, increased proliferation of human endothelial cells62, 
cardiac acceleration65, a regulation of calcium metabolism64 and 
insulin secretion66, an increase in body temperature, and a decrease 
in food intake66. Dr. Vignery, and her colleagues, here at Yale, have 
demonstrated that CGRP has potent immunosuppresive activity in 
vitro by virtue of inhibiting the production of IL-2 by T cells67. 
The activation of T lymphocytes leads to the production of IL-2, 
a lymphokine which initiates a cascade of cellular events. Among the 
cytokines produced by immune cells, IL-2 is the earliest growth 
factor produced by T cells upon stimulation by antigen and IL-1. IL-2 
is not only a potent T and B cell mitogen but also a direct activator of 
natural killer cells. Thus, the production of IL-2 is a critical step that 
influences the immune response. 
By virtue of its capacity to induce the proliferation and the 
differentiation of multiple T cell subsets as well as the release of 
cytokines, IL-2 plays a key role in the initiation and evolution of the 
immune reaction that leads to tissue remodeling or repair. In as 
much as the production of IL-2 has beneficial effects in immune 
defense mechanisms, its production can also be associated with 
tissue destruction that accompanies chronic inflammatory reactions 
and autoimmune diseases. Thus, local control mechanisms may help 
regulate immune reactions. 

Dr. Vignery has demonstrated that T lymphocytes express 
functional receptors for CGRP which prevents the production of IL-2 
by a cAMP-mediated inhibition of IL-2 gene expression67. 
From the evidence that has been presented in this section, it 
appears that CGRP plays both a regulatory and modulatory role along 
the neurovascular, neuroendocrine and neuroimmune axis. 
2.5 Non-Obese Diabetic (NOD) Mouse Model 
The NOD mouse represents a model in which autoimmunity 
against beta cells is the primary event in the development of insulin- 
dependent diabetes mellitus (IDDM). It serves as one of the best 
characterized and most widely used models of autoimmune diabetes. 
The NOD mouse was derived from a cataract developing substrain of 
outbred ICR/JC1 mice by selective breeding at Shianogi Laboratories 
in Japan in the early 80’s. Since then many substrains of NOD mice 
have been established which differ in diabetes incidence and time of 
onset. Typically 80-100% of female mice and 15-40% of male mice 
develop the disease between 3 to 6 months of age. In these mice the 
sex difference is attributed to the sex hormones, since castration 
increases the incidence of diabetes in males and decreases the 
incidence in females. Environmental factors, such as diet25, can 
influence the rate of development of the disease. Furthermore, 
animals protected from infections by maintenance in a pathogen free 
y,f 
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cages have higher incidence of diabetes1"*. Crowding of mice and 
frequent handling also elevates the incidence of diabetes, and this is 
believed to be due to stress. 
IDDM is a disease whose main clinical feature is 
hyperglycemia. In NOD mice this is easily determined by whole blood 
portable glucose monitor. However, in initial screenings it is more 
practical and less expensive to measure glucose levels in urine, since 
hyperglycemia inevitably leads to glycosuria. When persistent 
glycosuria is observed, then more acurate portable glucose 
monitoring can be initiated. 
The pathologic lesion leading to IDDM in both NOD mice and in 
humans is the autoimmune destruction of the insulin-producing beta 
cells in the pancreas. The course of the disease in mice can be 
followed by histological examination of the surgically removed 
pancreas. A typical longitudinal histologic examination demonstrates 
the following69: at 3-4 weeks of age, infiltrating immune cells 
surround the blood vessels (perivascular infiltration) but the islets are 
still clear. At 6-7 weeks, the infiltrating cells reach the islets (peri- 
islet infiltration). Between 10-12 weeks, the infiltrating cells 
penetrate into the islets (intra-islet infiltration) and the islets become 
swollen with lymphocytes. Following the onset of overt diabetes at 
14-20 weeks, the infiltrate disappears, leaving the islets greatly 
reduced in size and devoid of beta cells. 
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By staining with antibodies directed at markers of T ceils, B 
cells, and macrophages, it has been shown that macrophages 
predominate among the cells first infiltrating, followed by CD4 T 
cells, then by CD8 T cells and B cells69. Experiments employing 
adoptive transfer of T cells have shown that CD4 T cells from 
prediabetic NOD mice did produce insulitis following the transfer, 
but did not lead to islet destruction or hyperglycemia; the transfer of 
CD8 T cells did not produce insulitis or hyperglycemia. However, 
when CD8 T cells were transferred together with, or after CD4 T 
cells, autoimmune diabetes developed. Taken together with the data 
from the immunohistochemical analysis of the lesions, it seems that 
CD4 T cells home to the islets, attach themselves and proliferate, and 
enable the later-arriving CD8 T cells to reach the islets and engage in 
the destruction of the beta cells70. Antibodies do not appear to play 
any role in the pathogenesis of IDDM in either humans or mice, even 
though the presence of several antibodies have been detected before 
the onset of overt diabetes7172 73 . 
The development of diabetes in NOD mice is under the control 
of multiple genes. At least ten genes, both MHC and non-MHC 
related, mappped to nine different chromosomes have been shown to 
contribute to the susceptibility of NOD mice to diabetes. 
Susceptibility gene Idd-1 is located in the murine MHC on 
chromosome 17, and is a gene complex with two suceptibility loci, 
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the class II genes I-AJ3 and I-Ea. I-AJ3 gene is homologous to the 
human DLADQB 1*0302 IDDM-associated allele in having serine 
instead of aspartate at position 57 4. NOD mice do not express the 
other MHC class II product, I-E, owing to the mutation in the I-Ea 
gene. The absence of the I-E product is necessary for NOD diabetes. 
The introduction of a normal I-Ea, as a transgene in NOD mice, 
completely prevents diabetes7". However, evidence contrary to this 
was later presented by Podolin and Wicker indicating that the 
expression of I-E in NOD mice is not in itself sufficient to prevent 
diabetes6. 
The non-MHC susceptibility genes that play a role in NOD 
diabetes have been designated Idd-2, Idd-3, Idd-4, Idd-5, Idd-6, Idd- 
7, Idd-8, Idd-9 and Idd-10, and mapped to Chromosomes 9, 3, 11, 1, 
6, 7, 14, 4, and 3 respectively. The nature of each of the non-MHC 
susceptibility genes is less well defined in their effect on the disease. 
Development of diabetes is mediated through a multifactorial 
interaction between MHC class II genes and multiple, unlinked, 
genetic loci. Moreover, the NOD mouse demonstrates the critical 
interaction between heredity and environment. The difference in 
disease incidence and age of onset among various colonies, 
depending on the cleanliness of the housing conditions, illustrates 




Lastly, one should bear in mind that IDDM patients are 
genetically and probably pathogenically heterogeneous. Thus. NOD 
mice might represent only a part of the IDDM population. Use of an 
animal model to study human disease always requires cautious 
interpretation. 
2.6 Rat Insulin Promoter and Transgenic Technology 
Transgenic technology allows the scientist to incorporate and 
express a given gene in a specific tissue or cell type. In part, this is 
possible because of the remarkable ability of selective expression of 
specific genes by differentiated eukaryotic cells. For example, the 
beta cell of the pancreas is the only cell in the body that can express 
insulin even though the genetic information for expression of insulin 
is present in all the cells of the organism. The information of 
whether insulin or any other protein will be produced in the 
pancreas or in the brain is not contained within the coding sequence 
of the insulin gene: rather it is contained in a number of distinct 
transcriptional control elements located upstream of the mRNA 
initiation site. These transcriptional control elements collectively are 
referred to as the promoter region. Through recombinant DNA 
techniques a given gene could be attached to another promoter 
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region which would result in the expression of the given gene only in 
the cells where the promoter has a permit of a sort to act in. 
In the transgenic mouse that we created, the CGRP gene was 
linked to the rat insulin promoter, which would insure the targeted 
expression of CGRP to the beta cells of the pancreas. Along with the 
development of the transgenic technology in mid 80’s, the rat insulin 
promoter, which was first described in 1979 by Lomedico and 




3 MATERIALS AND METHODS 
3.1 Reagents 
Human CGRP, CGRP8-37, mouse amylin and human CGRP RIA were 
purchased from Peninsula Laboratories (Belmont). Complete Freund 
adjuvent and M-MLV reverse transcriptase were purchased from 
Gibco-BRJL (Grand Island). Keyhole Lympet Hemocyanin (KLH) was 
purchased from Calbiochem (La Jolla). Unless otherwise stated, all 
reagents were obtained from Sigma (St Louis) 
3.2 Antibodies 
The following Abs were used: guinea pig anti- human insulin 
(BioGenex, San Ramon), mouse anti-porcine glucagon (Sigma, St 
Louis), rabbit anti-human CGRP (Penninsula, Belmont), biotinylated 
rat mAb anti-mouse Ly5 (B220) (Caltag, South San Francisco, CA), 
biotinylated rat mAbs anti-mouse CD4, CD8a and CD4+red613 
(1/500) (GibcoBRL, Grand Island), biotinylated anti-mouse CD8+ 
(TIB 105, ATCC), anti-mouse CD4+red613 (1/500) (GibcoBRL, Grand 
Island, NY), anti-mouse B220+ and avidin-phycoerythrin 
(PharMingen, San Diego), anti-mouse-TCR+-FITC (H57-557, ATCC), 
donkey anti-guinea pig-FITC and -CyS^M donkey anti-mouse-FITC 
and -CyS^M, goat anti-rabbit-CyS^M (Jackson ImmunoResearch Lab, 
Inc., West Grove), streptavidin-phycoerythrin (Calbiochem, La Jolla, 
CA), goat anti- mouse Ig (H+L) coupled to magnetic beads (Biomags, 

8-4340G, Cambridge), hamster mAb anti-mouse CD3e (2C11-145. 
ATCC). 
3.3 Cells 
Cytotoxic T-Cell Line (CTLL) and T cell lymphoma EL-4 were obtained 
from ATCC (Bethesda). 
3.4 Construction Of The pRIP-hCGRP-Ex2 Transgene 
The human CGRP gene cloned into pGEM4 plasmid vector (Promega) 
was kindly provided by Dr. Gilbert Cote from MD Anderson Cancer 
Center in Houston, Texas. This construct was named pGEM4-CGRP. 
The TGCA splice site upstream of Exon 4 was deleted. The resulting 
gene preferentially leads to the production of CGRP mRNA as shown 
in Figure 5. pBS-SK-RlP plasmid vector containing the rat insulin 
promoter was kindly provided by Dr. Dominique Piearella from 
Howard Hughes Institute at Yale University School of Medicine. CGRP 
gene was excised out of pGEM4-CGRP using Hind III restriction 
enzyme, agarose gel purified, and ligated into the Hind III site of pBS- 
SK-RIP (Figure 6). The ligated DNA was transformed into DH5-a 
competent cells by electroporation using Bio Rad Electroporator 
(Settings: Capacitance 25 microFad. Resistance 200 ohms, Voltage 
2.5 V). Electroporated cells were grown in 1ml SOC (LB broth rich 
in glucose) medium for 1 hour at 37°C, and 150ul was plated onto 
■ 
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Ampicillin/agar plates and incubated overnight at 37°C. 48 colonies 
were picked and cultured overnight at 37°C in LB+Ampicillin 
medium. DNA plasmid miniprep was performed on all 48 cultures 
using the “boiling method” described by Maniatis78. 10 ul from each 
DNA plasmid miniprep was digested with Hind III to determine which 
sample contained the CGRP gene insert. To ensure the correct 
orientation of the inserted CGRP gene, plasmids containing the CGRP 
insert were subjected to further digests by Nhe I. Xmn I, Ail il, Apa I, 
Kpn I, and Spe 1. We had therefore constructed the pBS-SK-RIP- 
hCGRP (Figure 6). As discussed in the background section on CGRP 
the exon 1 of the Calcitonin gene is non-coding and only serves as a 
regulatory element which could interfere with the insulin promoter 
driven targeted expression of CGRP in the beta cells of the pancreas. 
Thus, the sequences upstream of BstB I site, which included Exon 1 
and Intron 1, were removed from the construct as follows. pBS-SK- 
RIP-hCGRP was double digested with BstBI and EcoR I. The digest 
was run on a 1% agarose gel, and the larger fragment, which 
contained the pBS-SK, RIP and Human CGRP from exon 2 onward, 
was purified by electroelution as described in Maniatis78. The ends of 
the purified fragment were ligated using a 27 base-polylinker (EcoRI- 
EcoRV-Xbal-BstBI, obtained from oligonucleotide synthesis services 
at Boyer Molecular Biology Center). Following ligation, DNA was 
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Figure 6: A: pBluescript SK (pBS- 
SK) plasmid. B: pBS-SK-RIP 
constructed by inserting rat insulin 
promoter (RIP) into pBS-SK 
between BamH I and EcoR I sites. 
C: pBS-SK-RIP-hCGRP 
constructed by inserting CGRPgene 
into pBS-SK-RIP at Hind III site. 
D: pRIP-hCGRP-Ex2 constructed 
by excising Exon 1 and Intron 
I with EcoR I and BstB I restriction 
endonucleases and ligating the 
ends of the larger fragment with 
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cultures, and mlnipreped as described above. This construct was 
named pRIP-hCGRP-Ex2 (Fig. 6). To insure the integrity of the new 
construct, it was subjected to partial restriction map analysis using 
EcoR I, Hind III, Xba I. BstB I, Xmn I and BssH I. 
pRJP-hCGRP-Ex2 was “maxipreped” and precipitated in CsCl 
column twice as described in Maniatis78. Ethidium bromide from 
purified DNA was extracted using water saturated Butanol. Plasmid 
DNA was precipitated with EtOH and resuspended in TE buffer. 
lOOul of the plasmid DNA was digested with Not I and Hind III to 
isolate the RIP-hCGRP-Ex2 sequence from the pBS-SK vector. The 
separation was performed on 1% agarose gel and the RIP-hCGRP-Ex2 
fragment isolated by dialysis. The isolated fragment was further 
purified using Elutip-d DNA column (CalBiochem). To desalt the DNA 
samples prior to injection into mouse embryos, they were dialysed 
with Millipore 0.05 micron round filter paper. DNA was quantified 
and diluted to the concentration of 5 ng/ml in sterile double distilled 
water. 
2 picol of this 5ng/ul RIP-hCGRP-Ex2 were injected into 
fertilized eggs from NOD mice, and implanted in the uterine horns of 
pseudopregnant BALB/c female mice using standard procedures79. 
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3.5 Screening of RIP-hCGRP-Ex2 Transgenic Mice and 
Establishment of Colonies 
3.5.1 Genomic DMA Preparation: 
Solutions: 1. Tail buffer - 50 mM Tris pH 8.0, 100 mM EDTA, 
lOOmM NaCl, 1% SDS 
2. Saturated phenol/chlorophorm/isoamyl alcohol 
(ratio 25:24:1) 
3. Chlorophorm/isoamyl alcohol (ratio 24:1) 
Approximately a 5 mm portion of the tails from 2 week old 
mice were excised. 700 ul of tail buffer and 25 ul of Proteinase K 
(lOmg/ml) were added to each of the tails in an 1.5 ml eppendorf 
tube and incubated overnight at 55°C. DNA was isolated by two 
phenol/chlorophorm extractions, followed by a single chlorophorm 
extraction. 600 ul of ice cold EtOH was added to the aqueous phase 
which was then precipitated in a microcentrifuge at 14,000 rpm for 
30 minutes. The supernatant was discarded, the pellet washed with 
70% EtOH and suspended in 100 ul of H20. DNA concentration was 
determined using a spectrophotometer. A reading of 1.0 optical 
density (O.D.) at 260 nanometer wavelenght represents to 50 ug/ml 
of double stranded DNA. 
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3.5.2 Tail DMA Analysis by Southern Hybridization: 
Solutions: Recipes for all of the following solutions described 
in Maniatis78. 
1. 20 x SSC 
2. Denhardt’s Solution 
3. Hybridization buffer - 6 x SSC, 0.5% SDS, 0.01M 
EDTA, 5x Denhardt’s Solution, 100 ug/ml 
denatured Salmon Sperm DNA. 
4. Denaturing Solution 
5. Neutralizing Solution 
10 ug of each tail DNA sample was digested with Pvu II and run 
on a 1% agarose gel. The gel was then bathed in 0.25 M Hydrochloric 
acid solution for 20 minutes. It was then placed in denaturing 
solution for two 20 minute intervals, followed by two 20 minute 
intervals in neutralizing solution. DNA was then transferred to a 
nitrocellulose membrane. Following the transfer, DNA was 
crosslinked to the membrane by ultraviolet crosslinker. This filter 
was prehybridized in hybridization buffer for 2 hours at 65°C. A RIP- 
CGRP probe, generated by excising a 647 bp fragment from the RIP- 
CGRP-EX2 plasmid using Xbal, was used to identify transgene 
positive mice. This probe was denatured by boiling for 5 minutes at 
95°C, was then added to the hybridization buffer and incubated 
overnight at 65°C in a shaking water-bath. The filter was washed 
• 
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successively with 3 x SSC + 0.1% SDS at 65°C two times, followed by 
0.3 x SSC + 0.1% SDS twice, and eventually 0.1 x SSC + 0.1% SDS at 
65°C. After the final wash was performed the filter was wrapped in 
SaranWrap and exposed onto a film with an intensifying screen at -70 
C for 36 to 48 hours. 
3.6 Immunohistology 
Tissue immunostaining was undertaken for twro reasons: (1) to 
ensure that CGRP was being produced in the beta cells of the 
pancreas and (2) to check whether CGRP was aberrantly expressed 
in any other peripheral organ. 
Pancreata were collected from F0 NOD-CGRP and NOD mice, fixed at 
4 °C overnight in periodate / lysine / paraformaldehyde fixative (Ref 
PNAS 18), processed sequentially through graded sucrose solutions 
[10%, 20%, and 30% (wt / vol)], and snap-frozen in tissue-Tek OCT 
(One-Touch, Miles (West Haven) by submersion in 2-methylbutane 
(EM Science, Gibbstown). 8-10 mm thick serial sections were 
collected onto gelatin-coated slides (Superfrost/Plus, Fisher 
Scientific, Pittsburg) and blocked with a solution containing 0.6 % 
Triton X-100 / 33% normal goat serum / 0.9 M NaCl / 0.2 M 
phosphate buffer, pH 7.4 for at least 2 hr at rt. The sections were 
then washed 3 times with a solution containing 0.3% Triton X-100 / 
4 M NaCl / 0.2 M phosphate buffer prior to being incubated with 
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rabbit anti-human CGRP (1/2000) for 2.5 hr at rt. This polyclonal 
antiserum was pre-incubated with 20 mg / ml of mouse amylin to 
eliminate its cross-reactivity with amylin. The sections were washed 
3 times as described above and incubated for 1.5 hr at rt with goat 
anti-rabbit-CY3™ (1:100). 
For the histoimmunochemical analysis of pancreatic islets from the 
NOD and NOD-CGRP colonies, half pancreata were fixed for 24 hr in 
10% phosphate-buffered formalin, paraffin-embedded, serially 
sectioned and stained with hematoxylin and eosin. The presence of 
mononuclear infiltrates, in and around capillaries and islets of 
Langerhans, along with the percentage of islets with peri-insulitis 
were recorded on twenty sections selected every 5 sections. The 
other half pancreata were processed for immunocytochemistry as 
described above. The primary antibodies used were as follows: 
guinea pig anti-insulin (1/50), mouse anti-glucagon (1/200), rabbit 
anti-human CGRP (1/2000), biotinylated rat mAbs anti-mouse Ly5 
(B220) (1/20), CD4 (1/20), or CD8a (1/20). The sections were 
washed 3 times as described above and incubated for 1.5 hr at rt 
with the appropriate secondary antibody as follows: donkey anti¬ 
guinea pig-FITC or -Cy3^M (1/100 and 1/200 respectively), donkey 
anti-mouse-FITC or -Cy3TM (1/100 and 1/200 respectively), goat 
anti-rabbit-Cy3TM (i/lOO), or streptavidin-phycoerythrin (1/200). 
The surface area of the lymphocyte infiltrate around each islet was 
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estimated morphologically using the non-specific labeling of the 
nuclei bv fluorescein. The percentages of CD4, CDS and Ly5 (B220) 
lymphocytes, labeled with phycoerythrin conjugate, was estimated 
and expressed as percent of total immune infiltrate. 
3.7 Islet Isolation and Culturing 
Solutions: 1. Hanks Balanced Salt Solution (HBSS) - For 
every 100 ml of HBSS use 1 ml penicillin-streptomycin (Gibco), 3.25 
ml Hepes (Gibco), 2 ml of 7.5% Bovine Serum Albumin (Gibco). 1 mg 
DNAse (Boehringer Mannheim) 
Islets were isolated from the pancreata of freshly sacrificed 
mice. To digest the pancreatic tissue, it was treated with 5 ml of 
HBSS for 5 minutes on ice. Supernatant was removed and 5 ml of 
0.075% of collagenase in HBSS was added and shaken for 5 
additional minutes. Above steps were repeated for two more times. 
After the third shake 5 ml of Bruff s + 5% Fetal Calf Serum was added 
to to each vial and incubated for 5 minutes at room temperature. 
This was a washing step and was repeated two more times. Following 
the final wash the vials were left in the washing solution and placed 
on ice until the the next step when islets were picked. Under the 
microscope the islets were identified as suspended white spheres, 




dish. The islets were cultured in Bruffs + 5% Fetal Calf Serum 
media. 
3.8 Bioactivity and Proliferation Assay for CGRP 
The murine T cell line EL-4 produces IL-2 in response to activation 
with PMA (ATCC). This line does not produce CGRP and CGRP 
inhibits its production of IL-2 in response to Phorbol 12-Myristate 
13-Acetate (PMA). Figure 7 graphically illustrates the principle 
behind the bioassay. EL-4 T cells are cultured for 24 hours in the 
presence of PMA 
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Figure 7: EL4/1L2 Bioassay Principle. A: Phorbol 12-Myristate 13-Acetate (PMA) 
stimulates EL-4 T cells to produce 1L-2 which in turn stimulates CTLE cells to 
proliferate. B: CGRP decreases IL-2 production bx EL-4 T cells. Decreased IL-2 
production ranslates into decreased CELL proliferation. 
(5ng/ml) and log2 dilutions of supernatant to be assayed for CGRP 
activity. Positive controls include medium supplemented with 
increasing concentrations of rat CGRP. Supernatants from EL-4 T 
cells are added to CTLL, a mouse cytotoxic T cell line whose 
proliferation depends on IL-2. Extent of proliferation is measured by 
the amount of [^H] Thymidine incorporation by CTLL. A dose- 
dependent response analysis of CTLL cells to recombinant human IL- 
2 is performed in each assay to define the IL-2 standard curve and to 
determine the concentration of IL-2 produced by EL-4 T cells and 
therefore estimate the potency of CGRP. 
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3.9 Breeding of Mice 
Mice were bred and kept in sterile filtered cages. For breeding 
purposes a positive transgenic male mouse was always placed in the 
same cage with two negative transgenic females and if successful 
impregnation was not observed within three weeks, different 
transgenic negative females were placed in the cage. When breeding 
a transgenic positive female mice, they were always placed with a 
single transgenic negative male mouse, and once again if 
impregnation did not occur in 3 weeks, the transgenic negative male 
mouse was replaced. The newborn progeny were screened for the 
presence of the R1P-CGRP transgene at the age of 2-3 weeks by tail 
DNA analysis. 
3.10 Diabetes Monitoring 
Animals were monitored for glycosuria every week using 
Chemstrip UG (Boehringer Mannheim). If animals were positive in 
two consecutive urine tests, blood glucose was measured using One 
Touch blood glucose meter (Lifescan, Inc.). Mice were considered 
diabetic when their blood glucose levels reached 250 mg/dl. 
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3.11 Statistical Analysis 
Results were analyzed using either the Student t test or the test 
for significance of difference between two proportions, when 
appropriate. To determine the number of animals needed to reach a 
power of 80% and an a level of 0.05 using a two tail test, we 




4.1 pRIP-hCGRP-Ex2 Construct 
As explained in materials and methods following the excision exon 1 
and intron 1 from pBS-SK-RIP-hCGRP, pRIP-hCGRP-Ex2 was derived 
(Figure 2). Both these constructs were subjected to restriction 
mapping by various endonucleases. The results of these digests are 
presented in Figure 8 and they show great agreement between the 
expected and the observed fragment sizes. 
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Figure 8: A: To ensure the proper engineering of the pRIP-hCGRP-Ex2 transgene, the 
pBS-SK-RIP-hCGRP and pRIP-hCGRP-Ex2 constructs were subjected to restriction 
mapping as shown below. B: Fragments originating from pBS-SK-RIP-hCGRP and pRIP- 
hCGRP-Ex2 are bold when differing in size. 
Lane # DNA Sample Restriction Expected 
Enzymes fragments (kb) 
l lkb Ladder 
2 Uncut pBS-SK-RIP- 
hCGRP 
12 
3 Uncut pRIP-hCGRP- 
Ex2 
9.5 
4 pBS-SK-RIP-hCGRP EcoRl & Hind III 3.5. 8.5 
5 pR!P-hCGRP-Ex2 EcoRI & Hind III 3.55, 5.95 
6 pBS-SK-RIP-hCGRP Xbal & Hind III 0.6, 2.95, 8.5 
7 pRIP-hCGRP-Ex2 Xbal & Hind III 0.6, 2.95, 5.95 
8 pBS-SK-RIP-hCGRP BstBI & Hind III 2.5, 3.55. 5.95 
9 pRIP-hCGRP-Ex2 BstBI & Hind III no 2.5, 3.55, 5.95 
10 pBS-SK-RIP-hCGRP XmnI 2.1, 2.3, 7.6 
11 pRIP-hCGRP-Ex2 XmnI 2.1, 2.3, 5.1 
12 pBS-SK-RIP-hCGRP EcoRl & Spel 0.6, 3.5, 3.7, 4.2 
13 pRIP-hCGRP-Ex2 EcoRI & Spel 0.6, 1.7, 3.5, 3.7 
14 pBS-SK-RIP-hCGRP EcoRl & BssHI 3.7. 8.3 
15 pRIP-hCGRP-Ex2 EcoRl & BssHI 1.2, 8.3 
16 lkb Ladder 
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4,2 Beta cells from NOD-CGRP transgenic mice express CGRP 
Three NOD-CGRP transgene positive founders were identified 
by Southern blot analysis of tail DNA (lines 42, 44. 46). Specific 
expression of the transgene was determined by 
immunoeytochemistry and reverse transcriptase polymerase chain 
reaction (RT-PCR). Among the three transgene positive lines, two (44 
and 46) expressed immunoreactive-CGRP in the pancreas, with mice 
from line 44 showing the strongest signal. Progeny from line 44 were 
selected for breeding and analysis. When islets from these NOD- 
CGRP mice were co-stained with anti-insulin Abs, the signal co¬ 
localized with that of CGRP (Fig. 9) indicating that CGRP was 
produced by beta cells. None of the other tissues examined (brain, 
lung, kidney, thymus, spleen, intestine, liver, bone marrow) from 
both NOD-CGRP and NOD littermates expressed detectable level of 
immunoreactive CGRP. Of note, immunoreactive-CGRP was detected 
in nerve endings present in most tissues examined, including the 
pancreas of both NOD-CGRP and NOD littermates. To investigate 
whether the CGRP transgene was expressed in other tissues, RNA 
was extracted from organs and isolated islets, and subjected to RT- 
PCR analysis. As expected PCR products were detected in the 
pancreas of transgene positive mice as well as in the kidney (Fig 
10A), a frequent site of expression of the rat insulin promoter81’82. No 
expression of RIP-CGRP was seen intissues other than pancreas and 
kidney even though we performed 35 cycles of PCR and followed it 
with Southern analysis. Cultured islets from NOD-CGRP mice, but 
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not from NOD littermates, expressed RIP-CGRP transcripts at all 
time points examined (Fig. 10B). 
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Figure 9: CGRP co-localizes with insulin in islet cells from NOD-CGRP mice. 
Frozen sections from pancreata of NOD-CGRP mice stained with anti-insulin 
antibodies (A) and anti-human CGRP (B) reveal the co-localization of insulin and 




Figure 10: Human CGRP is transcribed from die RIP-CGRP transgene. RNA 
extracted from pancreas, kidney, spleen, liver, lungs, thymus, brain and 
Langerhans islets of NOD-CGRP and NOD mice was analyzed by RT-PCR and 
the PCR products subjected to Southern blot hybridization using the RIP-CGRP 
probe. The predicted 440 bp RT-PCR product from RIP-CGRP mRNA was 
detected in the pancreas, in the kidney (A) and in the islets cultured for 24, 48 and 
72 hours {B) of NOD-CGRP transgenic mice. No signal was detected in 
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4.3 Beta cells from NOD-CGRP mice produce bioactive CGRP 
To investigate whether the transcripts encoded by the RIP- 
CGRP transgene were expressed by the beta cells as a biologically 
active peptide, supernatants from isolated islets from NOD-CGRP 
mice and transgene negative littermates were assayed for CGRP- 
immunosuppressive activity. Islet supernatants from NOD-CGRP 
mice inhibited the production of IL-2 by EL-4 cells (Fig. 11). The 
potency of 
Figure 11: Production of biologically active CGRP by islets from transgene positive 
(A, M ) and transgene-negative littermates (B, 0 ). One hundred islets per well were 
cultured in 0.5 ml of culture medium for one to five days. Immunosuppressive activity 
of the supernatant was assayed using the IL-2-producing mouse T cell lymphoma EL- 
4. In parallel EL4.IL-2 cells were cultured in either medium alone ( O and O) or 
supplemented with supernatant derived from islets and previously incubated with the 
antagonist CGRP 8-37 (O and O). IL-2 concentration in the supernatants was 
determined by fi'H] thymidine incorporation of CELL cells. 
g_ CGRP positive 
-H- CGRP positive 
-•- CGRP negative 
» CGRP negative 
0.1 1 10 
[EL4 supernatant], percent 
. 
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CGRP in these islet supernatants was comparable to that obtained 
with 10"® M human CGRP (data not shown). Preincubating EL-4 
cells with 10"5 M of the truncated form of CGRP (CGRP8-37) which 
acts as a CGRP antagonist67 prevented the inhibitory effect of the 
transgenic supernatants suggesting that the effect was indeed 
mediated by CGRP produced by the transgenic islets. No activity was 
detected in the islet supernatants from transgene negative 
littermates. This indicated that beta cells from NOD-CGRP mice 
produced active CGRP. 
4.4 Production of CGRP by beta ceils prevents diabetes in male and 
reduces the incidence in female NOD transgenic mice 
The incidence of diabetes in our NOD colony reached 71% in 
females after 46 weeks of age and 40 % in males after 63 weeks and 
was therefore similar to that reported by other authors83’84 (Fig. 12). 
While none of the male NOD-CGRP mice developed diabetes, 
26% of the female did. The incidence of diabetes was thus reduced 
by 63% in females aged 52 weeks and older and was significant 
(p<0.05) when using a two tail test78 (Fig. 12). Using the test for 
significance of difference between two proportions, the z value was 
superior to 4 in all groups indicating that the two proportions were 
significantly different at a 0.001 level. 
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Figure 12: Incidence of diabetes in NOD-CGRP transgenic mice. Glucosemia was 
monitored even• other week using One-Toucli Basic Meter. A reading of 250 mg/dl 
or more indicated the onset of diabetes. 
Age in weeks 
4.5 NOD-CGRP transgenic mice are immunocompetent 
To ensure that CGRP did not have a systemic effect on 
lymphoid development and function, we performed the following 
experiments. First, we determined whether T and B cell 
development was altered in NOD-CGRP mice. As indicated in fig 13A 
and Table 2, lymphocyte profiles in thymus, spleen and lymph nodes 
from NOD-CGRP transgenic mice were indistinguishable from those 
of negative littermates suggesting that CGRP production by beta cells 




Table 2. FACS analysis (in %) ofCD4+, CD8+, CD4+CD8+ and Ly5 B220 
lymphocytes in lymph nodes, spleens and thymus of 2 NOD control mice and 2 NOD- 
RIP-CGRP transgenic mice._ 
NOD NOD-CGRP 
CD4+ Lymph nodes 44/55 52/49 
Spleen 34/31 27/31 
Thymus 13/13 13/ 14 
CD8+ Lymph nodes 18/21 20/19 
Spleen 14/13 12/ 12 
Thymus 5/4 4/4 
CD4+CD8+ Lymph nodes 0.5 / 0.5 0.6 / 0.6 
Spleen 0.3 / 0.3 0.5 / 0.3 
Thymus 78/80 78/79 
B220 Lymph nodes 36/22 26/29 
Spleen 45/40 54/51 
Thymus nd nd 
lymphoid tissues. In addition, T cells responded normally to 
polyclonal activator such as anti-CD3 and to allogeneic stimulation in 
vitro, further suggesting that T cell differentiation was not affected by 
the local production of CGRP (Fig. 13B). We then analyzed whether 
CGRP could interfere systemically with the priming of naive T cells in 
lymphoid organs that do not express the transgene. Thus, we 
analyzed the antigen-specific T cell response to KLH after 
immunization in vivo with this antigen. As shown in figure 13C, NOD- 
CGRP mice responded to KLH immunization and the response was 
similar to that of transgene negative littermates. Thus, in NOD-CGRP 
mice, lymphoid cells appeared to develop normally and mice 

remained immunocompetent. These data indicated that CGRP had 
no apparent systemic effect, an observation which was corroborated 
by the low serum concentration of immunoreactive CGRP in NOD- 
CGRP mice, similar to that of transgene negative littermates (males: 































Figure 13: Expression of CGRP by pancreatic beta cells of the NOD-CGRP mice has no 
detectable systemic effect on the immune response. A: FACS profile of CD4+CD8+’ CD4 + 
and CD8+ T lymphocytes, and 8220 B lymphocytes from spleen, lymph nodes and thymus of 
NOD-CGRP and NOD littennates. B: anti-CD3 activation, allogenic and isogenic 
stimulation; allogenic stimulation was performed using as APCs spleen cel's from CBA/CA 
(H2k) mice. C: NOD-CGRP and NOD mouse lymphocyte response to KLH immunization. T 
cell-enriched lymph node cells from NOD (circles) and NOD-CGRP mice (squares) were 
cultured at increasing density (1,2 and 4 x 1 (P cells / well, black, grey and white symbols 
respectively) in Bruff medium supplemented with KLH (0.16 to 100 pg / ml). (squares, NOD- 
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4.6 The production of CGRP by beta ceils partially prevents peri- 
insultitis in NOD-CGRP males 
To investigate whether lymphoid cells infiltrated the pancreas 
of NOD-CGRP males which do not develop diabetes, their pancreata 
were analyzed histologically at different ages and compared to those 
from NOD littermates (Table 3). However, due to the late onset of 
diabetes (30 week) in NOD male, most animals were maintained alive 
expecting a possible delayed onset of the disease in NOD-CGRP mice. 
Thus, a limited number of animals were sacrificed for histochemical 
analysis of the pancreatas. 
Table 3. Incidence of peri-insulitis in NOD-CGRP and NOD male mice. 
Age, (weeks) Mice developping peri-insulitis, (%) Islets with peri-insulitis (%) 
NOD (n) NOD-CGRP (n) NOD (n) NOD-CGRP (n) 
13 100 (3) 25 (4) 25 (406) 25 (89) 
18-20 100 (4) 33 (6) 68 (271) 25 (336) 
While all male NOD mice had developed peri-insulitis by the 
age of 13 weeks, only 25% of NOD-CGRP male mice did so. At that 
age, only 25% of the islets presented peri-insulitis in both groups. By 
the age of 18-20 weeks, the percentage of transgene positive males 
with peri-insulitis increased to 33% while their percentage of islets 
presenting peri-insulitis remained constant (vs 68% in NOD male). 
Although the low number of mice observed in each group did not 
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allow statistical analysis, CGRP expression by beta cells appeared to 
reduce the incidence of peri-insulitis. 
4.7 The infiltrating leukocyte population is similar in NOD-CGRP 
and NOD littermates 
To characterize the pancreatic infiltrate from male NOD-CGRP 
and NOD mice, pancreata containing insulin-positive cells were 
subjected to immunocytochemical analysis using anti-CD4, -CD8 and 
-B220 Abs. The lymphocyte population surrounding the islets of 
transgenic negative mice during the peri-insulitis stage was 
composed of a majority of B220+ lymphocytes that represented more 
than 60% of the total infiltrate. CD4+ cells represented 30 % while 
CD8+ cells represented up to 40 % of the total infiltrate. Similar 
ratios were observed in the infiltrates from transgenic positive 
littermates in which the percentage of CD4+ and CD8+ cells reached 
10-20 % and 5-10 %, respectively. Comparable ratios of T and B 
cells surrounding the islets of NOD mice have been reported*"’’86. 
These data indicated that the local production of CGRP did not affect 
the composition of the immune infiltrate present during the pre¬ 




The present study demonstrates that the targeted production of 
the immunosuppressive neuropeptide CGRP to beta cells is sufficient 
to prevent the onset of diabetes in male and to decrease its incidence 
in female NOD mice. This prevention is most likely due to a local 
immunosuppressive effect of CGRP as it is not associated with a 
generalized immune suppression. Indeed, the average lifespan of 
transgenic animals was longer than nontransgenic littermates, and 
comparable normal mouse strains, suggesting that the localized 
expression of CGRP was not acompanied by undesirable side effects. 
Although the mechanism by which this immune suppression occurs 
locally has not been definitively elucidated, islets isolated from our 
transgenic mice produce active CGRP with a potency estimated to 
10"8 M CGRP, a concentration that prevents IL-2 and IFN-y 
production by Thl cells in vitro67. This suggests that the local 
concentration of CGRP released by beta cells in vivo may be sufficient 
to alter the onset of diabetes. 
Thl cells have been shown to accelerate diabetes in NOD mice*7 
and are most likely targeted by CGRP in our transgenic mice. CGRP 
may therefore inhibit the induction or expansion of autoreactive Th 1 
cells either directly as we reported earlier67 or indirectly by 
inhibiting antigen presentation by local antigen presenting cells such 
as dendritic cells as described in other models*8. Thl cytokines are 
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also thought to be responsible for the activation of other effector cells 
which can destroy beta cells. In fact CD8+ T cells, NK cells and 
mediators released by activated macrophages have been implicated 
in the destruction of beta cells*9. We can therefore postulate that 
CGRP might locally restore an immune balance by either repressing 
the production of deleterious Thl cytokines (IL-2. IFN-y and TNF-a) 
and/or favoring a Th2 response leading to the production of 
cytokines such as IL-4 which has been shown to be protective for 
diabetes"0. Furthermore, we cannot rule out that CGRP may act 
directly on other effector cells such as NK91 or macrophages92. Dr. 
Vignery previously has demonstrated that macrophages express 
functional receptors for CGRP4' and more recently that CGRP down 
regulates the production of TNF-a (Millet and Vignery. unpublished 
data). Additional characterization of the cells infiltrating the islets 
and determination of their cytokines produced in NOD-CGRP mice 
are required to address these issues. 
Importantly, although NOD-CGRP males do not develop the 
disease, they still exhibit a perivascular and peri-islet accumulation 
of lymphoid cells. While the proportion of islets surrounded by 
lymphoid cells appears lowered, the composition of the infiltrates 
does not appear modified by the expression of the transgene. If 
confirmed by further investigations, this would suggest that CGRP 
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might protect from diabetes by preventing the infiltration and clonal 
expansion of immune cells around the islets. 
Thus the local expression of the immunosuppressive peptide 
CGRP by beta cells prevents their destruction and therefore diabetes 
in NOD mice. This observation opens possibilities to treat or prevent 
diabetes by engrafting islets expressing CGRP into NOD mice. 
From the concept that Thl cells contribute to the pathogenesis 
of several organ-specific autoimmune diseases, targeted immune 
intervention aiming to restore an immune imbalance based on a cell- 
specific transgene expression of an immunosuppressive peptide 
appears as a promising approach. Similar targeted gene therapy can 
be applied to other organ-specific autoimmune diseases such as 
collagen-induced arthritis, Hashimoto's thyroiditis, Grave's disease or 
to conditions in which immune cells are beleived to be pathogenic 
mediators. 
Finally, an alternative and somewhat unlikely possibility which 
has not been disproven by our studies is that the transgene effect 
seen can be the result of the transgene having randomly inserted 
into, and thus disrupting the function of, a diabetes susceptibility 
gene. Since such susceptibility genes are mainly recessive, 
inactivating one allele would make the animal diabetes resistant. 
However improbable this and perhaps other explanations may seem, 
inherently uncertain nature of science forces us to humbly accept 
the fact that if 
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some event is improbable, that does not necessarily mean that it is 
impossible. 
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